CYTR - サイトレックス (CytRx Corporation)

CYTRのニュース

   CytRx Highlights Orphazymes Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C  2021/08/24 12:00:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (CytRx or the Company), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (NASDAQ:ORPH) ("Orphazyme") published the results from a Phase 2/3 trial of arimoclomol, an investigational heat-shock protein amplifier, in Niemann-Pick disease type C (NPC) in the peer-reviewed Journal of Inherited Metabolic Disease (JI
   CytRx reports Q2 results  2021/08/12 20:54:49 Seeking Alpha
   CytRx Comments on Quarterly Results and Recent Strategic Initiatives  2021/08/12 20:06:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (CytRx or the Company), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the second quarter ended June 30, 2021. In addition, CytRx recapped corporate developments as well as matters pertaining to its agreements with ImmunityBio, Inc. (NASDAQ:IBRX) (ImmunityBio) and Orphazyme A/S (NASDAQ:ORPH) ("Orphazyme"). T
   Kaposi Sarcoma Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Aphios, Bristol Myers Squibb, Cytori Therapeutics, CytRx, Eli Lilly and Company, GlaxoSmithKline,  2021/07/25 11:35:12 Jumbo News
This report studies the Kaposi Sarcoma Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Kaposi Sarcoma market segmented by company, region, type []
   CytRx inks securities purchase agreement for $10M  2021/07/13 12:36:57 Seeking Alpha
   CytRx inks securities purchase agreement for $10M  2021/07/13 12:36:57 Seeking Alpha

calendar